For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Ambev S.A. (ABEV) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Our current read (analysis of 2026-08-27): Designation Gem · Gem Score +45 (−100…+100 Quality+Value blend) · Quality 69 · Value 29 · Sentiment -39 (timing only, not weighted) · Composite fair value $4.11 vs $2.91 at analysis
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Ambev S.A.
ABEV NYSEAmbev S.A. ADR is the American depositary receipt of Ambev S.A., a leading beverage company based in São Paulo, Brazil. Ambev produces, distributes, and sells a broad portfolio of beers, draft beer, soft drinks, bottled water, teas, isotonic drinks, ready-to-drink cocktails, and other non-alcoholic beverages. Its brands include well-known names across Brazil, Latin America, Central America, and the Caribbean, serving both mass-market and premium consumer segments. The company operates an integrated beverage business that covers brewing, packaging, logistics, and commercial distribution to supermarkets, retailers, distributors, and on-premise outlets. Ambev S.A. ADR represents a consumer staples business with a wide regional footprint and a diversified product mix across alcoholic and non-alcoholic categories.
Price Overview
Price History (1 Year)
Revenue & Net Income Trend
Ambev S.A. is a foreign private issuer — it reports to the U.S. SEC once a year (on Form 20-F or 40-F) rather than filing the quarterly statements (10-Q) that U.S.-domiciled companies must submit. Our financial statements are read directly from SEC filings, so for this company only annual figures exist at the source.
This is a property of how the company files, not missing or broken data — its filing history shows 9 annual reports, the latest filed 2026-03-03, and no quarterly filings . The company may still publish quarterly results on its own investor-relations site.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 0.19
Total Equity: $17.20B
Shares: 15,683,900,000
Total Debt: $656.21M
Cash: $3.61B
EBITDA: $5.84B
Total Debt: $656.21M
Cash: $3.61B
Revenue: $17.10B
Revenue: $17.10B
Revenue: $17.10B
Total Equity: $17.20B
Tax Rate: N/A
Equity: $17.20B
Total Debt: $656.21M
Cash: $3.61B
Current Liabilities: $8.83B
Long-Term Debt: $430.05M
Total Debt: $656.21M
Total Equity: $17.20B
Shares: 15,683,900,000
Shares: 15,683,900,000
CapEx: -$889.41M
Shares: 15,683,900,000
Stock Price: $2.94
Net Income: $3.00B
Industry Benchmarks
Income Statement (Annual)
Last updated: Aug 26, 2026 3:32pm (42d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $14.1B | $15.4B | $15.4B | $17.3B | $17.1B |
| Cost of Revenue | $6.9B | $7.8B | $7.6B | $8.5B | $8.3B |
| Gross Profit | $7.2B | $7.6B | $7.8B | $8.9B | $8.8B |
| Operating Expenses | $3.9B | $4.2B | $4.2B | $4.7B | $4.3B |
| Operating Income | $3.3B | $3.4B | $3.6B | $4.2B | $4.5B |
| Net Income | $2.5B | $2.8B | $2.8B | $2.8B | $3.0B |
| EBITDA | $4.4B | $4.6B | $4.9B | $5.6B | $5.8B |
| EPS | $0.16 | $0.18 | $0.18 | $0.18 | $0.19 |
| EPS (Diluted) | $0.15 | $0.18 | $0.18 | $0.18 | $0.19 |
Balance Sheet (Annual)
Last updated: Aug 26, 2026 10:43am (42d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3.2B | $2.9B | $3.1B | $5.5B | $3.6B |
| Total Current Assets | $7.5B | $7.3B | $7.1B | $10.5B | $8.5B |
| Total Assets | $26.9B | $26.7B | $25.7B | $31.5B | $28.1B |
| Current Liabilities | $7.5B | $7.9B | $7.9B | $9.6B | $8.8B |
| Long-Term Debt | $436.6M | $540.2M | $426.8M | $421.7M | $430.0M |
| Total Liabilities | $10.6B | $10.6B | $10.2B | $12.2B | $10.9B |
| Total Equity | $16.3B | $16.1B | $15.5B | $19.3B | $17.2B |
| Retained Earnings | — | — | — | — | — |
Cash Flow (Annual)
Last updated: Aug 26, 2026 10:43am (42d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $4.4B | $4.0B | $4.8B | $5.1B | $4.7B |
| Capital Expenditure | -$1.5B | -$1.3B | -$1.2B | -$920.1M | -$889.4M |
| Free Cash Flow | $2.9B | $2.7B | $3.6B | $4.1B | $3.8B |
| Acquisitions (net) | -$25.9M | $-581,250 | -$9.0M | $2.0M | -$17.7M |
| Net Debt Issued / (Repaid) | -$414.4M | $8.7M | -$34.4M | -$22.4M | -$24.5M |
| Dividends Paid | -$513.2M | -$69.2M | -$105.4M | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | -$169.7M | -$135.6M | $548.4M | $2.0B | -$1.4B |
Growth Trends (YoY %)
Last updated: Aug 26, 2026 3:32pm (42d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +9.4% | +0.0% | +12.2% | -1.4% |
| Gross Profit Growth | +5.6% | +2.9% | +13.3% | -1.0% |
| Operating Income Growth | +3.6% | +6.5% | +15.8% | +7.0% |
| Net Income Growth | +14.1% | +0.3% | -0.4% | +7.4% |
| EBITDA Growth | +5.2% | +6.8% | +14.6% | +4.2% |
Dividend History (Last 20)
Last updated: Aug 22, 2026 9:53am (46d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-06-24 | $0.01 | — | — | — |
| 2025-08-11 | $0.02 | — | — | — |
| 2025-05-19 | $0.02 | — | — | — |
| 2025-03-18 | $0.02 | — | — | — |
| 2024-12-23 | $0.04 | — | — | — |
| 2023-12-22 | $0.15 | — | — | — |
| 2022-12-20 | $0.15 | — | — | — |
| 2021-12-20 | $0.02 | — | — | — |
| 2021-01-14 | $0.01 | — | — | — |
| 2020-12-18 | $0.08 | — | — | — |
| 2019-12-20 | $0.12 | — | — | — |
| 2018-12-19 | $0.08 | — | — | — |
| 2018-06-18 | $0.04 | — | — | — |
| 2018-02-01 | $0.02 | — | — | — |
| 2017-12-19 | $0.09 | — | — | — |
| 2017-06-26 | $0.05 | — | — | — |
| 2017-01-24 | $0.02 | — | — | — |
| 2016-12-22 | $0.06 | — | — | — |
| 2016-11-01 | $0.05 | — | — | — |
| 2016-07-12 | $0.03 | — | — | — |
Deep Analysis
Risk : Reward — upside vs downside from this company's own quarters
Not computed yetNarrative Economics
market-narrative step).
Growth Outlook
Analyzed 2026-08-26 15:41The question every valuation on this page silently assumes: is this company likely to grow? Judged forward — the business, its category, the world — against what's already printed.
Claude Reading
Starting with the raw numbers: Ambev is doing exactly what a mature EM staples company should do. Revenue grew from $14.12B (2021) to $17.10B (2025), a 4.9% CAGR in USD despite BRL depreciation — the constant-currency organic story is materially better. Operating margin expanded from 23.4% to 26.4% across the five years, net margin from 17.4% to 17.6%, and ROIC is a genuinely impressive 25%. The balance sheet is fortress-grade: $3.61B cash against $656M debt, D/E of 0.04, and $3.85B FCF on a $45B market cap = 8.5% FCF yield. This is not a distressed name; it's a cash machine trading at 7.3x EV/EBITDA.
But the bear case has teeth the synthesis underweights. Revenue actually declined 1.4% YoY in 2025 ($17.33B → $17.10B), and the five-year "growth" is heavily FX-translation noise — Brazilian beer volumes have been flat-to-declining, and the premiumization runway is narrower than global brewer comps suggest. AB InBev's controlling stake (~62%) means minority holders are structurally subordinated to parent-company capital allocation priorities; the 1.1% dividend yield is startlingly low for a "cash return" story and reflects that ABI has redirected Ambev's cash toward its own deleveraging via intercompany flows and tax-efficient distributions rather than fat dividends to ABEV ADR holders. The insider tape shows sales outpacing open-market buys (awards aren't buys), which is neutral-to-slightly-negative for a stock supposedly this cheap.
Where I diverge from the prior models: the Valuation Synthesis says $3.77 fair value (+29.9% upside) and Market Forces calls it a value trap — these are directly contradictory and the synthesis doesn't reconcile them. I lean closer to Market Forces but not all the way. A $17B revenue base compounding at ~3% real (post-FX normalization), 26% op margins, and 8.5% FCF yield deserves a re-rating IF Brazilian rates fall and BRL stabilizes — Selic is coming down from 15%, which historically correlates with LATAM staples multiple expansion. But "IF" is doing heavy lifting. The Narrative layer is correctly identifying that there's no story premium here; the question is whether the discount is rational (my view: mostly yes) or excessive (synthesis view). At 15x P/E vs Heineken/Carlsberg at 18-20x and ABI parent at ~19x, the ~20% discount is roughly appropriate for BRL risk plus minority-holder governance drag, not a screaming bargain.
Contrarian counter to my own skepticism: at 7.3x EV/EBITDA with net cash, if you get any BRL tailwind and any volume stabilization, this re-rates to 9-10x quickly — that's 25-35% upside plus the dividend and buyback. The downside is genuinely limited because you're already below replacement cost of the distribution network and buying below the no-growth DCF floor. Committing: I partially agree with the synthesis that the stock is cheap, but I dissent from the "+29.9% upside" framing — that treats the Brazil risk premium as mispricing rather than rational. Fair value is closer to $3.30-3.50, not $3.77, implying 12-20% upside plus ~1% dividend. That's a decent risk/reward but not a table-pounder, and it requires patience for a macro catalyst that may take 12-24 months. Not a value trap in the destruction sense, but a value trap in the dead-money sense is a real risk if Brazilian rates stay high or Argentina/Central America deteriorate further.
GPT Reading
Ambev looks like a very good business priced like a merely acceptable one. The raw numbers show a company that has grown revenue from $14.1B in 2021 to $17.1B in 2025, while lifting operating income from $3.31B to $4.52B and sustaining net income around $2.8-3.0B through multiple macro regimes. That is not a melting-ice-cube profile. Gross margin is still 51.4%, operating margin 26.4%, and net margin 17.6%—excellent economics for a consumer staples business in emerging markets. More important, cash conversion is real: $4.74B of operating cash flow and $3.85B of free cash flow against only $889M of capex. On a $45.2B market cap, that is an 8.5% FCF yield; against a business with net cash of roughly $3.0B after subtracting just $656M of debt from $3.61B of cash, that looks plainly inexpensive. EV/EBITDA at 7.3x for a dominant brewer with 17%+ ROE and 25% ROIC is closer to a cyclical industrial than a branded consumer franchise.
What stands out is that the market is treating flat near-term sales as if they invalidate the quality of the franchise. Yes, 2025 revenue of $17.10B was down 1.4% from $17.33B in 2024, but operating income still rose to $4.52B from $4.22B, and net income rose to $3.00B from $2.80B. That means pricing, mix, productivity, or cost discipline are doing real work. A business that can grow EBIT 7% on slightly lower revenue is not in distress; it is showing pricing power and operating control. Over the full 2021-2025 period, operating margin expanded from 23.4% to 26.4%, and free cash flow remains comfortably above earnings quality concerns. The current ratio under 1.0 does not worry me in this context because the balance sheet is essentially ungeared. If anything, the combination of near-zero leverage and strong cash generation suggests excess conservatism rather than hidden fragility.
The strongest argument against this view is that the market may be right to capitalize these earnings at only 15x because growth is simply too low to deserve more. Revenue CAGR of 5.2% over four years is not exciting, earnings CAGR of 3.4% is middling, and the latest year did show a top-line decline. A skeptic would also note that the dividend yield is only 1.1%, so investors are not being paid much current income while they wait for a rerating. If Brazil and broader LatAm currencies remain weak, reported dollar results can stagnate even if local-currency operations perform reasonably well, which is a real issue for ADR holders. There is also a fair challenge embedded in the margins: 51% gross and 26% operating margins are already high, so future upside may rely more on volume or premiumization than on additional efficiency. If category growth is mature and competitive intensity rises, today’s “cheap quality” can become a long-lived value trap.
I weigh those objections less heavily because the current valuation already assumes a lot of that disappointment. At $2.94, investors are paying about 2.7x sales and 15.2x earnings for a category leader throwing off nearly $4B of annual free cash flow with a fortress balance sheet. That is not a heroic multiple. Even if earnings only hold around $2.8-3.0B and free cash flow stays in the $3.5-3.9B range, the stock is not demanding much. The issue is not whether Ambev becomes a growth stock; it is whether a high-return, net-cash staples franchise should trade this cheaply. I think no. I do not need a big multiple rerating to justify upside—just sustained evidence that revenue can stabilize and margins stay above 25%. On those conditions, something closer to 17-18x earnings, or roughly $3.50-$4.00 per share, is reasonable.
What would change my mind is straightforward. If the next annual print shows another revenue decline of more than 2% alongside operating margin slipping back below 24% and free cash flow falling meaningfully below $3.2B, then the bear case of structural stagnation would be winning and the current multiple would make sense. Likewise, if cash starts shrinking because capital allocation becomes less disciplined or debt rises materially from today’s trivial level, the quality argument weakens fast. But if Ambev can post even low-single-digit revenue growth with EBIT holding above $4.4B and FCF above $3.6B, the market is underestimating the durability of the franchise.
Grok Reading
Ambev’s numbers describe a cash compounder that has largely finished growing its top line but has not finished extracting economics from the franchise. Revenue slipped from $17.33B in 2024 to $17.10B in 2025 (−1.3%), yet operating income rose from $4.22B to $4.52B and net income from $2.80B to $3.00B. That is pure margin work: operating margin at 26.4%, gross margin locked near 51%, ROIC at 25.1%. Free cash flow of $3.85B against a $45.2B equity value and only $656M of debt (net cash of roughly $3B) produces an FCF yield near 8.5% and an EV/EBITDA of 7.3x. Five-year revenue CAGR of 5.2% and earnings CAGR of 3.4% confirm the mature-earner label; the recent −1.4% revenue print simply makes the maturity obvious. At $2.935 the market is paying roughly 15x trailing earnings for a net-cash, high-ROIC regional monopolist—cheap relative to developed-market brewers, and cheap relative to the cash the business actually throws off.
The contradiction worth catching is between the valuation synthesis (composite fair value ~$3.77–$4.11, ~30% upside) and the market-forces “value trap” call. The trap argument treats Brazil FX, weak real consumption, and category maturity as permanent haircuts that justify a structural discount forever. The raw ledger pushes back: the company converted more than 22% of sales into FCF last year, carries a debt-to-equity of 0.04, and still expanded operating profit while volumes stagnated. That is not a business whose economics are eroding; it is a business whose volume is flat and whose capital structure and cost discipline are excellent. Narrative intensity is minimal and the −23% DCF discount is almost entirely a Brazil macro premium—rational, but already large. At 7.3x EV/EBITDA you are not paying for a re-rating story; you are being paid a high single-digit free-cash yield to own the dominant Latin American brewer while the macro discount sits in the price.
The strongest case against this read is straightforward and quantitative. Top-line growth has stalled: 2025 revenue is essentially unchanged from 2024, the multi-year CAGR is only mid-single digits, and earnings growth of 3.4% annually is nothing to underwrite a multiple expansion on. A 15x P/E is not distressed for a no-growth emerging-market consumer name facing structural currency volatility and soft real beer volumes; developed peers at 18–22x have cleaner currencies and clearer premiumization runways. Dividend yield is only 1.1% despite $3.85B of FCF, so the “income compounder” pitch is weaker than the cash-flow screen suggests—capital is being retained or used elsewhere rather than aggressively returned. If Brazil’s consumer stays soft and the real weakens further, the dollar FCF that looks so attractive today shrinks, and the stock can sit at 7x EV/EBITDA for years. That is the value-trap path, and the recent flat revenue print is the first data point a skeptic would underline.
I would flip toward a clear overvalued or avoid stance if full-year revenue declines again by more than 2–3% in dollar terms with operating margin compression below 24%, or if FCF falls under $3B while net cash is spent down without a corresponding capital return. I would flip more bullish if revenue re-accelerates to a sustainable 4%+ CAGR with stable margins, confirming the stagnation was cyclical rather than structural, or if the dividend/payout policy is reset to put the FCF yield more visibly in shareholders’ hands.
Qwen Reading local experiment · off-panel
The number that decides this case is the operating margin trajectory: 23.4% in 2021, 22.2% in 2022, 23.6% in 2023, 24.4% in 2024, and 26.4% in 2025. Four consecutive years of expansion on a revenue base that has grown from $14.12B to $17.10B (5.2% CAGR) means the earnings story is being written by cost discipline and mix, not volume. Net income of $3.00B in 2025 is the highest in the five-year series, up 7.1% from $2.80B, and there is no visible one-time item inflating it — the operating income of $4.52B supports it cleanly. Free cash flow of $3.85B on $4.74B of operating cash flow (after $889M capex) is a 22.5% FCF margin on revenue, and the balance sheet carries $3.61B cash against only $656M of debt, a net-cash position of roughly $2.95B. The debt-to-equity of 0.038 is not an artifact here; it is consistent with a mature consumer franchise that has no structural need for leverage. ROIC of 25% and ROE of 17.5% are the kind of returns that, in a developed-market consumer staples peer, would command 20x or more.
Building the EV bridge explicitly: $45.18B market cap minus $2.95B net cash gives an enterprise value of approximately $42.2B. Against $3.85B FCF, that is 11.0x EV/FCF. Against the implied EBITDA of roughly $5.8B (backing out from the stated 7.26x EV/EBITDA), the multiple is unremarkable. The P/E of 15.1x on $3.00B of earnings is the number the market is actually anchoring on, and for an EM consumer staples leader it sits in the middle of the 13–20x band that the sector typically occupies. The 8.5% FCF yield is the most compelling single data point in the briefing: a company generating a quarter of its revenue as free cash, with a net-cash balance sheet and a 25% return on invested capital, is not being priced as a growth story, but it is not being priced as a broken one either. The 1.1% dividend yield looks low for the sector and may reflect a data artifact or a policy shift; I would not build a thesis on it without confirmation.
The prior models split in a way that brackets the truth. The Valuation Synthesis lands at $3.77 (adjusted from $4.11), which implies roughly 25x trailing earnings or 19x EV/FCF — a multiple that belongs to a developed-market premium brand, not a Brazil-concentrated brewer with flat top-line. I disagree with that target; the raw data does not support a 25x P/E when revenue is down 1.3% year-over-year and the beer category in the core market is mature. On the other side, Market Forces calls this a "classic value trap" and "structural deterioration," but the data contradicts that framing: operating margin has expanded 300 basis points over four years, FCF has grown from roughly $3.5B to $3.85B, and there is no revenue collapse — the 2025 dip of 1.3% is a mild pullback after a 12.2% jump in 2024, not a structural break. The "insider selling" tag is also overread: the three S-Sale transactions total roughly 310K shares, worth about $900K at the current price, which is 0.002% of a $45B float. The A-Awards on the same dates are standard grants. This is noise, not conviction.
The strongest case against my read is the revenue line itself. Five years of data show $14.12B → $15.44B → $15.45B → $17.33B → $17.10B. The 2024 jump was likely FX-assisted (a stronger real against the dollar inflates USD-reported revenue), and the 2025 print shows that the underlying volume story is flat. If the real stabilises or weakens, the 26.4% operating margin — already at the high end of the company's historical range — has limited room to expand further, and the earnings growth that justifies a 15x multiple evaporates. A smart bear would also point to the 0.96 current ratio and the fact that Ambev's competitive set includes AB InBev, which has greater scale and a more diversified geographic footprint; Ambev is a subsidiary with a Brazil concentration that the parent does not carry. The "steady-compounder" narrative the market has assigned to this stock is accurate but also a ceiling: there is no re-rating catalyst visible in the data, no new product cycle, no geographic expansion, no M&A. The stock is a cash machine, and the market is paying a Brazil risk premium that is rational, not irrational.
What would change my mind in either direction. A quarterly print (the briefing provides no quarterly data, which is a genuine gap) showing revenue growth above 3% in local currency would confirm that the 2024 dip was cyclical and the 5% CAGR is intact, pushing fair value toward $3.40–$3.50. Conversely, two consecutive quarters of negative local-currency revenue growth, or an operating margin that reverts below 24%, would validate the value-trap thesis and pull fair value toward $2.50–$2.60. A material change in AB InBev's capital-allocation policy toward Ambev — a special dividend, a buyback, or a strategic review — would be the single most likely catalyst to close the EM discount, and the briefing does not show any such event.
On the numbers as they stand, 15x earnings, 11x FCF, 25% ROIC, net cash, and four years of margin expansion is a fair price for a Brazil-concentrated consumer franchise with flat revenue. The stock is not cheap enough to be a buy on fundamentals alone, and it is not broken enough to be a sell. The 8.5% FCF yield provides a floor, but the absence of a growth narrative provides a ceiling.
Big-3 Panel — where each AI stands
Advanced Analysis Forensic deep-dive · separate lenses
The business shows the profile of a mature, well-run consumer staples operator. Revenue grew from $14.1B (2021) to $17.1B (2025), gross margin held in a tight 49-51% band and expanded to 51.4%, and operating margin stepped up from 23.4% to 26.4% — genuine operating leverage, not accounting flatter. Net income of $3.0B and FCF of $3.85B in 2025 (FCF/NI ~1.28x, 5-yr OCF/NI 1.66x) point to earnings backed by cash, corroborated by accruals of -6.6% of assets and Beneish M of -2.73.
Verify before trusting this (5)
- Volume vs price/mix split in 2025 to see if the revenue dip is FX or organic weakness
- Segment breakdown Brazil beer vs NAB vs CAC vs LAS - concentration risk
- Dividend/JCP payout policy and cash returned to shareholders vs FCF
- Any pending tax litigation (Brazilian tax cases have historically been material for Ambev)
- Relationship and cash flows with parent AB InBev
The composite fair value of $4.11 and signal-adjusted $3.77 bracket a deserved price roughly 15-30% above the $2.91 quote. The three methods cluster tightly (EPV floor $3.48, DCF $4.04, anchored P/E $4.87), which is reassuring - no single runaway model is doing the heavy lifting, and the EPV floor alone sits ~20% above spot. Earnings quality is high, so no haircut is warranted, and the Strong quality grade justifies pricing at least at the EPV floor. That means the market is embedding a persistent Brazil/FX/mature-category discount rather than mispricing the cash flows outright. What is priced in: flat-to-declining volumes, structural BRL weakness, and no re-rating on premiumization. What would have to go right to justify a move to $3.77+: currency stabilization plus continued margin expansion - plausible but not guaranteed. Margin of safety exists (~20% to EPV, ~30% to composite) but it is the kind of discount you find often in EM staples, not a dislocation. Call it modestly cheap with a decent dividend while you wait.
Verify before trusting this (4)
- Organic volume trend in Brazil beer segment in next print
- BRL assumptions embedded in the DCF vs current spot
- Dividend/capital-return trajectory - key support for deserved value
- Any one-off tax or hedging items distorting reported earnings power
The market tape is modestly risk-on, but that tailwind barely reaches ABEV — beta 0.26 means the beta-chasing money is renting AI, cyclicals and high-multiple growth, not a Brazilian brewer. The prevailing narrative is 'steady compounder' at minimal intensity: nobody is telling a bull story here, no cult flow, no re-rating catalyst. What sentiment ABEV does attract is the 'sell Brazil / EM FX risk' framing, which is a persistent low-grade headwind rather than an acute one. The recent 3.4% drop on no news, and negative short-term momentum against a positive long-term drift, fit that picture: passive selling / FX mark-to-market rather than a narrative break. Analyst tone appears muted; there is no revision cycle pushing the story either way. Net: gentle but real headwind — the tape is helping other names, and the EM-defensive-with-no-story bucket is exactly the wrong archetype to catch a risk-on bid, while any risk-off wobble or BRL weakness lands directly on this ticker.
Verify before trusting this (4)
- BRL/USD direction and Brazil rate-cut path — the single biggest sentiment lever on ABEV
- Any shift in EM-equity flows or a Brazil-reform narrative that could ignite a story
- Sell-side target revisions or a change in consensus tone post next print
- Beer-category sentiment (volume trends, GLP-1 discourse) at the global brewer peer level
The relevant world is Latin American nominal demand, not global volume. High Brazilian policy rates and a firm US 10y (4.7%) keep the BRL under pressure, which mechanically suppresses USD-reported results even when local-currency net revenue per hectoliter rises. Soft commodity and packaging costs are the offsetting tailwind now flowing through the P&L. Structurally, beer per-capita consumption in Ambev's core markets is mature, so growth must come from mix, non-alcoholic adjacencies and distribution economics rather than litres. Brazil's tax reform is the one genuinely new external variable that changes the medium-term earnings equation.
When we made this prediction on Aug 27, 2026, ABEV was $2.89. We expect it to be $3.45 by Feb 2027, and we consider it great value under $2.60. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 27, 2026.
Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.
Post-Report Due Diligence NOTES
Evidence for a closer look, not a verdict — no score or designation on this page has been changed by it. Items marked material are ones where a conclusion above moves to the other side of the price.
adjusted_earnings
flips down 25%
cost_of_capital
flips up 25%
shares
flips up 25%